Year All202420232022202120202019 Altamira Therapeutics Provides Update on Nasdaq Listing Oct 04, 2024 Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray Sep 27, 2024 Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results Sep 24, 2024 Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024 Sep 20, 2024 Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering Sep 19, 2024 Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering Sep 17, 2024 Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia Sep 16, 2024 Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11 Sep 03, 2024 Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark Aug 23, 2024 Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances Aug 16, 2024
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray Sep 27, 2024
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024 Sep 20, 2024
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia Sep 16, 2024
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11 Sep 03, 2024
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark Aug 23, 2024
Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances Aug 16, 2024
